Xtant Medical (NYSEAMERICAN:XTNT) Releases Earnings Results, Misses Estimates By $0.05 EPS

Key Points

• Xtant Medical missed quarterly expectations: The company reported a loss of $0.07 per share, $0.05 worse than consensus, while revenue of $23.03 million fell short of the $24.88 million estimate.
• Shares remain near the lower end of their 52-week range: XTNT opened at $0.45, compared with a 52-week range of $0.39 to $0.95, and has a market capitalization of approximately $62.6 million.
• Analysts remain bullish despite the earnings miss: BTIG maintained a Buy rating with a $1.00 price target, while institutional investors own 69.33% of the company.

Xtant Medical (NYSEAMERICAN:XTNT - Get Free Report) released its earnings results on Tuesday. The medical device company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.05), FiscalAI reports. The firm had revenue of $23.03 million during the quarter, compared to the consensus estimate of $24.88 million. Xtant Medical had a net margin of 1.50% and a return on equity of 3.68%.

Xtant Medical Stock Performance

Shares of XTNT stock opened at $0.45 on Tuesday. The company has a market capitalization of $62.56 million, a price-to-earnings ratio of 44.64 and a beta of -0.13. The company has a debt-to-equity ratio of 0.17, a quick ratio of 1.64 and a current ratio of 3.34. Xtant Medical has a 52 week low of $0.39 and a 52 week high of $0.95. The company has a 50-day simple moving average of $0.44 and a 200 day simple moving average of $0.51.

Wall Street Analysts Forecast Growth

Separately, BTIG Research reiterated a "buy" rating and set a $1.00 price objective on shares of Xtant Medical in a research note on Wednesday, May 13th. Two investment analysts have rated the stock with a Buy rating, According to MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $1.00.

Institutional Investors Weigh In On Xtant Medical

Institutional investors have recently made changes to their positions in the stock. Wiregrass Investment Management LLC acquired a new stake in shares of Xtant Medical during the 4th quarter worth approximately $81,000. Renaissance Technologies LLC raised its holdings in shares of Xtant Medical by 28.8% during the 4th quarter. Renaissance Technologies LLC now owns 919,860 shares of the medical device company's stock worth $721,000 after buying an additional 205,945 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Xtant Medical by 4.6% during the 3rd quarter. Vanguard Group Inc. now owns 2,355,671 shares of the medical device company's stock worth $1,529,000 after buying an additional 104,159 shares during the last quarter. Nantahala Capital Management LLC lifted its position in shares of Xtant Medical by 500.3% during the 2nd quarter. Nantahala Capital Management LLC now owns 68,394,000 shares of the medical device company's stock worth $50,543,000 after buying an additional 57,000,000 shares during the last quarter. Finally, Mink Brook Asset Management LLC boosted its stake in Xtant Medical by 125.8% in the second quarter. Mink Brook Asset Management LLC now owns 109,466 shares of the medical device company's stock valued at $81,000 after buying an additional 60,997 shares in the last quarter. 69.33% of the stock is currently owned by institutional investors.

Xtant Medical Company Profile

Xtant Medical, Inc is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company's product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.

The company's offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source